Cargando…

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma

BACKGROUND: Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described. METHODS: All cabozantinib‐treated mRCC patients from January 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colomba, Emeline, Alves Costa Silva, Carolina, Le Teuff, Gwénaël, Elmawieh, Jamie, Afonso, Daniel, Benchimol‐Zouari, Axelle, Guida, Annalisa, Derosa, Lisa, Flippot, Ronan, Raynard, Bruno, Escudier, Bernard, Bidault, François, Albiges, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530538/ https://www.ncbi.nlm.nih.gov/pubmed/35903892 http://dx.doi.org/10.1002/jcsm.13021

Ejemplares similares

Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
por: Guida, Annalisa, et al.
Publicado: (2020)

Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
por: Cerbone, L., et al.
Publicado: (2021)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma
por: Derosa, Lisa, et al.
Publicado: (2016)

Renal Cell Carcinoma with bone metastases isn’t always bad
por: Ruatta, Fiorella, et al.
Publicado: (2019)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

804TiP CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
por: Albiges, L., et al.
Publicado: (2020)

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma
por: de Vries-Brilland, Manon, et al.
Publicado: (2023)

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
por: Schmidinger, Manuela, et al.
Publicado: (2022)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Impact of Preemptive Postoperative Pressure Support Ventilation and Physiotherapy on Postoperative Pulmonary Complications after Major Cervicofacial Cancer Surgery: A before and after Study
por: Salama, Guillaume, et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
por: Donskov, Frede, et al.
Publicado: (2019)

The treatment landscape in thyroid cancer: a focus on cabozantinib
por: Weitzman, Steven P, et al.
Publicado: (2015)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
por: Ma, Xuhui, et al.
Publicado: (2022)

Phase II Study of Cabozantinib in Patients With Bone Metastasis
por: Choy, Edwin, et al.
Publicado: (2022)

Cabozantinib for the treatment of solid tumors: a systematic review
por: Maroto, Pablo, et al.
Publicado: (2022)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

SAT479 A Case of Thyroiditis Cause by Cabozantinib
por: Bulchandani, Sheetal, et al.
Publicado: (2023)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
por: Belhechmi, Shaima, et al.
Publicado: (2023)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

A rare cutaneous adverse effect secondary to cabozantinib therapy
por: Growcott, Siona, et al.
Publicado: (2018)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
por: Deng, Shanshan, et al.
Publicado: (2021)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
por: Cella, Chiara Alessandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v5l2aqq26ecv5q8rirfl82juqc